NCT00612196View on ClinicalTrials.gov

A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

December 31, 2007

Conditions
Healthy
Interventions
DRUG

TB-402

Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes

DRUG

Placebo

Trial Locations (1)

DK-2100

Cyncron Clinical Research Unit, Copenhagen

Sponsors

Lead Sponsor

ThromboGenics
All Listed Sponsors
collaborator

BioInvent International AB

INDUSTRY

lead

ThromboGenics

INDUSTRY

NCT00612196 - A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter